Scandinavian Micro Biodevices (SMB) has launched its new diagnostic device: QuickVet Analyzer. The device brings novel ‘point of care’ testing to the clinic.
The QuickVet Analyzer and QuickVet COAG test cartridge provide analytical results in pets’ blood samples to help diagnose a range of conditions such as:
Investigating potential coagulation problems is an important pre-operative procedure.
SMB Chief Executive Officer, Mr Ole Kring, said: “The QuickVet Analyzer is simple to use, requires no routine maintenance and delivers results of high precision.”
The SMB device brings state of the art, ‘lab-on-a-chip’ concept from human diagnostics to the veterinary clinic, giving vets diagnostic test results in approximately ten minutes. Instead of waiting until the next day for the result, vets can offer pet owners an instant diagnosis.
The Quickvet Analyzer uses individual test cartridges based on microfluidic technology. The first test cartridge to be launched - the QuickVet COAG test - will analyse the intrinsic activated partial thromboplastin time (aPTT) and extrinsic partial thromboplastin time (PT) coagulation cascade from citrated whole blood in just minutes at an unmatched precision level of 7% CV in the relevant diagnostic range.
With touch screen operation, the instrument requires minimal training and is very user-friendly – the vet just adds a blood sample on the disposable cartridge and reads the result on the 7” colour screen.
The Quickvet COAG test is the first of several test cartridges being rolled out by SMB, which will be used in conjunction with the QuickVet Analyzer. They will all use whole blood samples and provide novel in-clinic diagnostic capabilities within the areas of infectious diseases, parasites and parasite transmitted diseases, toxicology, hormones, oncology and cardiology.
For further information on the QuickVet Analyser and QuickVet COAG test cartridges please contact:
Mr Ole Kring CEO Scandinavian Micro Biodevices ApS Gammelgaardsvej 87C DK-3520 Farum Denmark http://www.quickvet.net/ Telephone: +45 203 378 58
Boehringer Ingelheim has released details of research presented at the 29th World Veterinary Congress which shows dogs with congestive heart failure (CHF) due to myxomatous mitral valve disease (MMVD) live longer when treated with pimobendan (Vetmedin®) compared with a commonly used ACE inhibitor.
The results of the QUEST trial, the largest international study of its kind to be conducted amongst dogs with congestive heart failure, are due to be published in the Journal of Veterinary Internal Medicine (JVIM) later this year.
The condition myxomatous mitral valve disease (MMVD) accounts for approximately 75% of all cases of CHF in dogs2. MMVD is associated with the thickening of the cusps of the mitral valve (one of the main one-way valves within the heart), affecting the flow of blood from the heart to the rest of the body. Although there is no cure for CHF due to MMVD, there are treatments available to manage the condition, improving the quality and length of the dog's life.
Professor Jens Häggström, lead investigator of the QUEST trial from the University of Uppsala, Sweden, commented that "the QUEST trial is a significant milestone in our efforts to reassure both, veterinarians and dog owners, that there is compelling evidence to show that pimobendan is an effective treatment for CHF that prolongs their dog's life and providing pet and owner with more quality time together."
The QUEST trial was a randomised, positive-controlled, multi-centre trial conducted at 28 sites across 11 countries, and is the largest study of its kind ever conducted in veterinary cardiology. The study compared a pimobendan group with a group treated with benazepril hydrochloride on top of background diuretic therapy. The trial spanned three years and followed dogs to death, euthanasia or treatment failure leading to withdrawal from the trial.
Research by Boehringer has also shown that over 50% of dog owners in the UK are unaware that their dog may be at risk of heart failure. Heart disease affects one in four dogs over seven years of age, and the lack of knowledge about this serious, life-threatening condition suggests that there is a need for better education amongst dog owners on how to recognise the disease, and how to maintain their dogs' heart health.
Dermatologist Anthony Chadwick, aka the webinar vet, is offering VetSurgeon members a 30% discount on the cost of a forthcoming series of webinars. Just enter the word vetsurgeon in the discount box at webinarvet.com.
The series kicks off on the 17th June, when John Innes from Liverpool University will be talking about diagnosing forelimb lameness. On the 24th, Alan Robinson will be talking about pet healthcare schemes and on July 1st, Pip Boydell will discuss vestibular disease. Finally, on July 8th, Anthony will close the second series with a look at atopic disease, focusing on new and novel treatments.
For those of you that haven't yet experienced a webinar, and would like to 'try before you buy', there is a free webinar on 10th June (9pm-10pm), in which Martha Cannon, one of only 3 feline specialists in the UK, will present an update on feline infectious disease. Click here to register and if you enjoy the presentation, you will still be able to register for the series at the discounted price.
Eli Lilly and Company, which owns Elanco Animal Health, has announced an agreement to acquire Novartis Animal Health for approximately $5.4 billion in cash.
Lilly says that on completion of the deal, Elanco will be the second-largest animal health company in terms of global revenue. It will also solidify its number two ranking in the U.S., and improve its position in Europe and the rest of the world.
As part of the agreement, Lilly will acquire Novartis Animal Health's nine manufacturing sites, six dedicated research and development facilities, a global commercial infrastructure with a portfolio of approximately 600 products, a pipeline with more than 40 projects in development, and an experienced team of more than 3,000 employees.
The transaction is expected to be completed by the end of the first quarter of 2015, subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act, similar requirements outside the U.S., and other customary closing conditions.
John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer said: "Animal health continues to represent an attractive growth opportunity for Lilly. We intend to keep Elanco and to take advantage of the substantial synergies between our animal health and human health businesses.
"Significant investments in our animal health business in recent years have enabled Elanco to double its revenue since 2008, leading the industry in growth. Global trends suggest continued sustained demand for animal health products in the years ahead. Through this acquisition, which moves Elanco to top-tier in the industry, we intend to create value for our shareholders by adding to our promising pipeline of innovative animal health assets, increasing sales through a larger commercial footprint, and improving efficiencies and lowering costs."
Dechra Veterinary Products has announced the appointment of Bob Parmenter as managing director of its UK business.
Commenting on his appointment, Bob said: "I'm pleased to have joined Dechra at a very exciting stage of the company's development. I've been following the growth of Dechra over recent years and with its acquisition of VetXX in January, I believe that the business is now strongly placed to further establish itself as a leading player in the animal health industry."
Having spent nearly 40 years in the industry, Bob Parmenter has previously worked for Schering-Plough, Mallinckrodt Veterinary, Pitman-Moore, Coopers Animal Health and ICI Pharmaceuticals. "My career path has enabled me to experience all aspects of the animal health market. I'm confident my industry-wide knowledge will provide Dechra with additional experience as we continue to build our reputation and strengthen our UK market position."
Former MD Giles Coley, who joined Dechra in 1999 and has managed the UK business since 2003, has been promoted to European Pharmaceutical and Export Sales Director. As a member of Dechra Veterinary Product's European Board he will be responsible for co-ordinating pharmaceutical sales across Europe and developing the company's export sales.
CEVA Animal Health, manufacturer of pheromonatherapy products, D.A.P.® and Feliway®, has launched a new website - http://www.petfireworkfear.co.uk/ - and a new leaflet and waiting room poster to support its ‘Remember, remember your pets this November' campaign which is backed by the PDSA, FAB (Feline Advisory Bureau), the APBC (Association of Pet Behaviour Counsellors) and Sound Therapy 4 Pets.
The website features a comprehensive range of information including hints and tips on preparing pets for the firework festivities, how to spot signs of stress in cats and dogs, what to do if pets go missing or are injured, fireworks and the law and information on pheromonatherapy.
"The new site is a one stop shop for information on how to look after pets during the firework season and the precautions that owners should take to help pets cope with their fear of loud noises," says Lucy Brett, product manager at CEVA Animal Health. "Veterinary practices can help highlight these precautions by linking their websites to the ‘Remember, remember your pets this November' site."
A downloadable PR toolkit is also available from the website to enable veterinary practices to highlight the campaign to local pet owners. To request a copy of the ‘Remember, remember your pets this November' information pack, which includes details on CEVA's ‘Promote Your Practice' competition, please call Lucy Brett at CEVA on 01494 781510.
Hill's Pet Nutrition and Cat Professional are working in partnership to improve knowledge of feline lower urinary tract disease by giving complimentary copies of 'Caring for a cat with lower urinary tract disease' by UK feline specialists Dr Sarah Caney and Professor Danièlle Gunn-Moore to veterinary professionals and owners of cats affected by the condition.
Feline lower urinary tract disease is thought to affect up to 10% of cats, with particular prevalence in the indoor cat population and it is often a complex and distressing condition for cat owners to tackle.
Hill's has sponsored 1000 copies of 'Caring for a cat with lower urinary tract disease' , and is giving away vouchers which allow the recipient to visit the Cat Professional website (http://www.catprofessional.com/) to download an interactive copy of the book.
'Caring for a cat with lower urinary tract disease' is the third title in the successful 'Caring for a cat' series. Renowned cat behaviourist and bestselling author, Vicky Halls reviewed the book in glowing terms: "Feline lower urinary tract disease is a complicated subject for owners to fully appreciate so it is wonderful, at last, to have one book that contains all the necessary information that can be recommended to everyone"Hill's Pet Nutrition are distributing the complimentary vouchers to owners who contact their customer service freephone line for advice on the condition (0800 282438 - 9am - 4pm, Monday to Friday). Veterinary Professionals using the free Urolith Analysis Service offered by Hill's, or the Hill's Veterinary Technical Enquiry Line to gain help and advice on nutritional management of Feline Lower Urinary Tract diseases are also able to claim a complimentary voucher to redeem.
Adrian Pratt, Veterinary Affairs Manager for Hill's comments "FLUTD is a difficult disease to manage, let alone explain to fully to an owner. What Sarah and Danielle have done here is fantastic and will help owners better understand their cat's problem. That can only be good for the pet"
Bayer Animal Health, the maker of Veraflox, has produced a new animation which explains the considerations veterinary surgeons should take into account when choosing which antibiotic to prescribe.
The animation outlines the key steps that should be taken when faced with a suspected bacterial infection and includes factors such as culture and sensitivity testing, resistance and the mutant prevention concentration.
The company says it produced the animation in response to research it carried out last year in which nearly 500 veterinary professionals (465 practising vets and 45 students) participated.
48% said they felt that not enough is being done to educate veterinary professionals on the responsible use of antibiotics and how to avoid exacerbating the urgent issue of antimicrobial resistance.
Vicky McAlister, Group Product Manager at Bayer said: "In response to this research Bayer is developing a suite of educational resources to arm vets with practical and applicable tools that help them look beyond the 'tip of the iceberg' of bacterial infections, educating about not just the clinical cure, but bacteriological cure, too."
The animation is part of a wider awareness programme entitled ‘What Lies Beneath‘ in which Bayer says it aims to better understand the challenges the veterinary industry faces when prescribing antibiotics, so that additional tools can be developed to help vets confidently use antibiotics responsibly.
The programme will also include a series of webinars led by experts in various fields including veterinary medicine, laboratory diagnostics experts, behavioural psychologists and microbiologists. The webinars are due to be released later in the year, and will present a different perspective on common issues such as compliance, how to make appropriate antimicrobial choices and the approach to and interpretation of relevant diagnostic tests.
The RCVS has brought out a new publication to help members of the veterinary and veterinary nursing professions understand their legal and professional obligations regarding controlled drugs.
Controlled Drugs Guidance is a consolidation of existing advice and guidance on controlled drugs from a number of organisations including the RCVS itself, the Veterinary Medicines Directorate (VMD), the British Small Animal Veterinary Association (BSAVA) and the Home Office. The guide also gives details of the existing legislation concerning controlled drugs, namely the Misuse of Drugs Act and associated regulations.
The guidance provides advice on a variety of topics to reflect the common queries the RCVS Advice Team receives, such as storage, destruction and disposal; keys and keyholders for controlled drugs cabinets; controlled drugs in vehicles; and veterinary nurses administering controlled drugs.
The publication also deals with specific controlled drugs such as ketamine which, on 30 November 2015, was rescheduled to a Schedule 2 controlled drug, meaning that it is now subject to the same strict storage, prescription, dispending, destruction and record-keeping requirements as other medicines in this Schedule.
Laura McClintock, Standards and Advisory Manager at the RCVS, said: “We hope that this publication will help members of the profession navigate the often complex legislative and professional requirements regarding controlled drugs, as well as imparting best practice advice on how they should be stored and disposed and so on.
"This publication has also been endorsed by our colleagues in the Home Office, VMD and BSAVA and, because this is an area that is subject to regular change, we will make sure to keep it up-to-date as and when the regulations change."
The publication is available to download from the RCVS website at www.rcvs.org.uk/publications
The RCVS Council has announced its agreement with wholesale reform of the College’s governance arrangements to improve the efficiency and accountability of its decision-making processes.
The changes agreed by Council included almost halving the number of Council members and formalising lay and veterinary membership.
Under the proposals approved by Council it would be reduced to 24 members – comprising 13 elected veterinary surgeons (constituting a majority of Council), six appointed laypeople, three members appointed on behalf of the UK veterinary schools and two veterinary nurses. There would also be the option to appoint an additional member on behalf of any allied professions that RCVS Council may choose to regulate as associates of the College.
Professor Stuart Reid, Senior Vice-President of the RCVS and Chair of the Governance Panel that developed the recommendations, said: "I am delighted that Council so fully supported our proposals for a new structure. The new composition will ensure that both veterinary nurses and laypeople have a guaranteed place at the Council table, as well as maintaining a majority of elected veterinary surgeons and important input from the veterinary schools.
"The proposal recognises the unique nature of the RCVS and will allow us to expedite our decision-making process, making us more fleet of foot and better able to respond to the needs of the profession and the public. It has also been constructed to allow Council to evolve its position, ensuring it remains relevant into the future. If all goes well we hope that the changes could come into force as soon as March 2017."
Liz Cox, the Chair of VN Council, particularly welcomed the changes in respect of veterinary nursing representation on RCVS Council, adding: "It is an historic decision for veterinary nurses and one that has been long awaited. It is only right that those who work so closely alongside veterinary surgeons in practice should have a direct input into regulation that affects us all."
Council’s approval of the recommendations was the culmination of two years of debate and consultation with the profession and other stakeholders. This included a formal consultation by the Department for Environment, Food and Rural Affairs (Defra) last year which garnered 52 responses – including from the British Veterinary Association - most of which were supportive. Different options for reform had, in turn, been developed by a Governance Panel, chaired by Professor Reid, which was set up by Council in March 2015 to consider various options.
Defra will now run a short informal consultation to provide those who responded to the initial consultation the opportunity to comment on the proposed reforms. If no issues are raised Defra officials will seek approval from the Government to proceed with a legislative reform order (LRO) to make the necessary changes to the Veterinary Surgeons Act.
This LRO will be scrutinised by parliamentary committee and voted on in both the House of Commons and House of Lords. Once this has been passed there will be a three-year transitional period, agreed by Council members, during which Council’s numbers would be gradually reduced.
The range will include Vetoryl 20mg, 30mg and 60mg hydrolysed chicken flavoured tablets, which can be broken into halves or quarters.
The new Vetoryl tablets will come in packs of 30 tablets, although no word from Dechra as to when they'll arrive.
Thomas Johnson, Vetoryl brand manager at Dechra, said: “We are delighted that Vetoryl Flavoured Tablets for Dogs will soon be available, which will provide vets and pets owners with easy to administer, flavoured tablets to provide additional dosing flexibility.
"This, together with our commitment to providing extensive technical support and resources, will ensure that Vetoryl continues to be the UK’s leading licensed medical treatment for Cushing’s syndrome.”
Pfizer, manufacturer of the wormer Strongid™-P has launched a new promotional campaign. Love your horse is based on simple, straightforward and unbiased educational messages to help ensure the optimum health and wellbeing of horses and ponies in the UK.
Pfizer's veterinary adviser Ben Gaskell said: “Simplistically, the three key tools for the horse owner to understand are diagnostics, worming and pasture management. If these tools are used in combination with specialist advice, then the horse owner will be able to provide a sustainable, reliable and cost-effective worm control strategy for their horse.”
At the core of the campaign is a new range of four highly informative and uncomplicated leaflets directed at every type of horse owner: Do you need to worm; Choosing and using the right wormer; Managing your pasture and Worming and Your new horse.
“Each leaflet has been designed to work as a stand-alone piece or can be presented as a smart, matching series of four,” said Helen Shirley, brand manager for Strongid™-P. “The leaflets can be displayed in-store in a distinctive counter-top leaflet dispenser and are supported by eye-catching point of sale materials including posters and balloons." The new campaign packs will be rolled out to all stockists from early June, supported by a dramatic new Love your horse advertisement in national equestrian trade and consumer titles.
The campaign will build up momentum over the summer months and into autumn’s double dosing time with a series of authoritative, no-nonsense features and news stories from Strongid™-P’s veterinary advisor Ben Gaskell.
For further information please email: Strongid-P@pfizer.com
Genitrix has launched a new system called Osteokine, which produces Platelet-Rich-Plasma (PRP). PRP, an autologous solution containing therapeutically significant concentrations of platelets, is known to accelerate the healing of injuries and is already widely used in human medicine. It is increasingly being used in the treatment of horses.
The Osteokine system, developed by German company Orthogen which also manufactures joint therapy Irap, comprises two interconnected blood bags.
The system involves taking citrated whole blood from the horse and placing it into the first, red-capped Osteokine bag for processing in a centrifuge. The plasma and platelets are then transferred to the second bag, and a second centrifuge process separates the plasma and generates a pellet of PRP, which is extracted and used to treat the horse from which it was taken.
Treatment with PRP has been shown to accelerate wound healing in all kinds of tissue particularly tendons and ligaments and has also been used in bone healing. It has been noted to reduce perioperative traumatic pain while the higher collagen content provided by PRP can create improved scar resistance.
Commenting on the launch of the Osteokine system in the UK, Rob Watkins, Marketing Director of Genitrix, said: "Therapeutic care of equine lameness is an area of particular expertise for Genitrix and the innovative treatments we've brought to market, including Acell, HY50 and Irap already form part of the staple ‘toolkit' of many equine vets.
"The benefits of PRP in terms of accelerating wound healing and vasculerisation are already widely accepted as are the advantages of an autologous approach in terms of eliminating the risk of disease transmission. To date, however, the process of extracting PRP has proved complex and expensive and only provided in specialised laboratories.
"Osteokine, in contrast, offers a cost-effective approach based on a system which is simple to operate in practice and takes only 20 minutes. We believe it offers a highly effective approach to treating wounds and injuries in horses."
For further information on Osteokine, contact Genitrix on 01403 786345.
Vygon Vet, a division of Vygon (UK) Ltd, has announced the launch of its website - www.vygonvet.co.uk.
Vygon has been supplying the veterinary market for 15 years. The new website means the company's products can now be bought direct online. The range includes: Vascular Access, IV Management, Needle-Free Devices, Respiratory, Digestive Tract, Regional Anaesthesia, Tissue Adhesive, Urinary & Rectal Tract and Theatre Products.
In addition to product information and technical data, the website offers guidance notes and tips about basic procedures.
Les Davies, Managing Director of Vygon (UK) Ltd said: "The launch of the new website demonstrates our commitment to the veterinary market and we hope that it not only enables veterinary professionals to order our products with ease, but that they also find the guidance notes and advice a valuable resource for their practice."
Vygon Vet products can also be ordered by telephone or through your veterinary wholesaler.
Scientists at the Royal Veterinary College, contributing to a programme to tackle some of the most harmful and widespread endemic diseases that commonly affect farmed animals in the UK, have developed a severity estimation calculator for post-weaning multi-systemic wasting syndrome (PMWS).
Post-weaning multi-systemic wasting syndrome (PMWS) is a common disease of young pigs in the U.K. It is extremely debilitating, causes considerable suffering and poor welfare, and has a high mortality of up to 30%. It is estimated that the disease costs the UK farming industry £30m per year.
The £2.4m project - headed by Professor Dirk Werling from the Royal Veterinary College and funded by the Biotechnology and Biological Sciences Research Council (BBSRC) through its "Combating Endemic Diseases For Farm-Animal Sustainability" programme (CEDFAS), the British Pig Executive (BPEX), and two industrial partners, Pfizer Ltd (UK) and BioBest - aims to identify why PMWS occurs and to develop new methods of controlling the disease.
One key-component of the project is the direct involvement of British pig farmers, thereby guaranteeing that pigs in Britain will be the first to benefit from this research, while collaboration with a major international pharmaceutical company will ensure that new veterinary products will be made available to pig farmers worldwide.
Now, two members of the team, Dr. Barbara Wieland and Pablo Alarcon-Lopez, a second year PhD student, have developed a novel approach to quantify severity of PMWS based on morbidity and mortality data and presence of porcine circovirus type 2 (PCV2). They applied factorial analyses, using data collected from 147 pig farms in England to identify variables contributing to variation in PMWS severity in a biologically meaningful way.
Together with other known variables linked to PMWS, the resulting factors were used to derive an algorithm for PMWS severity. The derived algorithm was used to develop a PMWS severity calculator, which now can be used by farmers directly to assess the PMWS severity on their own farm (http://www.bpex.org.uk/articles/300874).
The levels of PMWS severities identified on farm level can now be used to identify risk factors related to the different severity-categories, to assess the efficacy of PCV2 vaccination and to investigate the economic impact of potential control measures on a farm.
The RCVS has been out promoting the profession, the Practice Standards Scheme (PSS) and its new 'Find a Vet' search tool to animal owners at BBC Countryfile at Blenheim Palace last week.
The RCVS stand was designed to look like a veterinary practice, complete with waiting room, consulting room, prep room, operating theatre and RCVS Accredited Practice logos.
The team from the College handed out around 1,500 ‘Find a Vet’ canvas bags containing 'Find a Vet' and Practice Standards Scheme leaflets and merchandise, and persuaded over 200 people to take part in special ‘Find a Vet’ and PSS-themed games and competitions.
These included having to find a veterinary surgeon or nurse around the showground (volunteers from RCVS Council and VN Council, including RCVS President Chris Tufnell and VN Council Chair Liz Cox, along with David Catlow, Neil Smith, his dog, Fire, Lucy Bellwood and Amber Richards).
The College reports that there was also a continual stream of children eager to pretend to be veterinary surgeons and veterinary nurses for the day and have a go at the on-stand ‘animal examination’ and ‘animal surgery’ activities. All this gave rise to plenty of photo opportunities, which parents and competition entrants were encouraged to share on social media, to help spread the word about the College’s activities.
Ian Holloway, RCVS Head of Communications said: "This was the first time the RCVS had been to such a large-scale and high-profile public event, and it provided a superb opportunity to explain to animal owners who we are and how we can help them.
"We had a great deal of interest in our new Find a Vet service, and people also seemed reassured that there was a scheme in place to accredit veterinary practices around the country. Having attended both the London Pet Show and BBC Countryfile Live this year, we now plan to increase the number of animal owner events we attend next year, to further raise public awareness of the RCVS Practice Standards Scheme and our Find a Vet service."
For more pictures of the event, see: https://flic.kr/s/aHskEQkDPc
The company says its new brand has also been designed to communicate choice more clearly, thereby making vets' busy lives a little easier.
Malcolm Dickinson, Category Manager at NVS, said: “As a familiar and trusted brand, we’re always listening to our customers and designing products that closely meet their needs.
"We understand the challenges vets are facing, including rising costs and supply chain issues.
"That’s why we’re always looking to help relieve the impact on the day-to-day burden of the profession with the right products that help deliver the very best animal care.”
The new brand will be on display at Stand P20 at the London Vet Show.
Vets Now, the out-of-hours emergency services provider is to launch the Vets Now Hospital service in Glasgow city centre, where it will offer emergency and critical care together with a range of specialist referral options.
This follows on the heels of The University of Glasgow Small Animal Hospital, a new £15 million facility which opened at the end of August.
Vets Now says that the new hospitals and the range of clinical services on offer to the profession and pet owners will make the west of Scotland a centre of excellence in advanced clinical care for animals.
The opening of the two facilities will also offer both organisations a new platform on which to develop further their long standing relationship through future collaboration in the areas of teaching, training and investigation into animal disease.
Vets Now Group Managing Director, Richard Dixon said: "The opening of the two facilities presents a number of opportunities for both organisations to work collaboratively to develop teaching and training for undergraduates, residents, interns and nurses, and to work together to gain further understanding into animal disease through clinical investigation and the practice and promotion of evidence based medicine."
Professor Stuart Reid, Dean of the Faculty of Veterinary Medicine at the University said: "The expanded service which will be offered by the Small Animal Hospital and the new Vets Now Hospital obviously presents an enhanced range of choices for pet owners and first opinion vets in Scotland and an opportunity for both organisations to work collaboratively to ensure that undergraduates and clinical professionals have access to the best training and opportunities to develop professionally. We have enjoyed a mutually beneficial relationship for a number of years and we look forward to the new opportunities which the opening of the two hospitals will bring in the future."
The Small Animal Hospital opened on 31 August. The first Vets Now Hospital will open in Glasgow on 31 October.
Researchers from the School of Veterinary Sciences at the University of Bristol have had a study into domestic dogs' fear responses to noise published in Applied Animal Behaviour Science.
According to the University, the study provides an important insight into dogs' fear of noises, and could improve our understanding of behavioural signs of fear or anxiety.
In the study two approaches were taken to investigate the occurrence of, and risk factors for, behaviours caused by a fear of noise: a postal survey of dog owners to investigate general demographic factors and a structured interview of a sub-set of owners to gather more detailed information.
It seems that while owners are often aware of their pet's behavioural response when exposed to a loud noise, they do not necessarily recognise it as being indicative of fear or anxiety. This has relevance both for awareness of compromised welfare, and the methodology for surveying such behaviour.
According to the researchers, other behavioural signs, such as decreased activity or salivation, may not be as easily recognised by owners as signs of fear, and may be under-reported. Also, signs of urination, salivation and destruction may make owners disappointed or angry, and this may influence their interpretation that such behaviours are associated with fearfulness.
The risk factors for owner-reported fear of noises included:
The researchers suggest a dog's early life experience is an important factor in the development of fear responses to specific loud noises.
Dr Rachel Casey, European Specialist in Veterinary Behavioural Medicine and Senior Lecturer in Companion Animal Behaviour and Welfare at Bristol University, said: "Our results suggest that the characteristics of dogs, their early environment, and exposure to specific loud noises are involved in the development of fear responses to noises. Interestingly, less than a third of owners sought professional advice about treatment for their pet's response to noises."
Disappointingly, less than a third of owners currently seek professional advice about treatment for their pet's fear. The researchers recommend there is a need for veterinary surgeons to increase awareness among the general dog owning public that treatment is both available and effective in dealing with fears of loud noises, and to direct them towards appropriate sources of help.
Information for vets and dog owners on finding an expert to help treat behaviour problems including fear of noises can be found at www.rspca.org.uk/findabehaviourist
Paper: Fear responses to noises in domestic dogs: Prevalence, risk factors and co-occurrence with other fear related behaviour, Emily J. Blackwell, John W.S. Bradshaw, Rachel A. Casey, Applied Animal Behaviour Science, published online 22 January 2013.
Providing a service for everyone from the richest to the poorest, veterinary surgeons probably have a better insight than most to the effects of inequality in society.
Whilst most people can probably think of one or two government policies which contribute to inequality, Sebastian's fully-referenced book is perhaps the first to identify the entire alphabet's worth, and collate them in an easily digestible format (it's only a 45 minute read).
The book is available in hardback on Amazon for £10, or as an e-book for £5.99
Sebastian is on VetSurgeon.org to answer your questions about and discuss how government policies create inequality in society, here: https://www.vetsurgeon.org/001/nonclinical/f/off-duty-discussions/30455/the-a-z-of-inequality
Although you certainly don't have to have bought or read his book to take part in the discussion, you should find it £5.99 well spent.
https://www.amazon.co.uk/Z-Inequality-Sebastian-Chambers-ebook/dp/B09ZVN1HDW
FMDMost of you will be aware that IP8 was declared yesterday. This is a farm in the POZ that was slaughtered on suspicion after detection during surveillance visits. This has lead to further slight changes in the boundaries of the PZ and SZ. These were early lesions and initial laboratory results confirm this.
The epidemiology of the spread of FMD in the area north of Egham suggests that cattle on 4 premises in the vicinity of IP8 have been exposed to infection either via possible aerosol or fomite spread and are likely to develop disease. These premises will be culled as dangerous contacts.
BLUETONGUEThe various zones for controlling Bluetongue have now been defined. These are difficult to describe because they use roads etc. as boundaries but detailed maps and description of the boundaries are available at:
http://www.defra.gov.uk/animalh/diseases/notifiable/bluetongue/pdf/declaration-bt-pzcz290907.pdf
When farms straddle a road that is a boundary the whole of the farm is classed as being in the zone. It may be possible to put parts of a holding that is outside the zone as a separate unit with consultation with local Animal Health office.
The movement restrictions between the various FMD and BT zones are available at
http://www.defra.gov.uk/animalh/diseases/notifiable/bluetongue/movements/index.htm
Defra are worried that farmers are not reporting cases of BT because they feel there is nothing that can be done so why bother. It is still a notifiable disease and there is a need to monitor spread for various trade implications. There are, of course, likely to be welfare considerations with clinically affected cases. These will need to be addressed with veterinary consultation and may involve symptomatic treatment or euthanasia.
The prevalence of the disease in infected herds/flocks is still low with 1:53 and 1:190 being affected on surveillance.